Archive for May, 2008
Biotech Implosion: Favrille (FVRL)
Tuesday, May 27th, 2008Submitted by BioHealth Investor Blog
Novadel Pharma (AMEX: NVD) shares look ripe for the picking at these price levels, so much so that insiders can’t keep their hands off them.
The specialty pharmaceutical company develops oral spray versions of drugs already on the market, and has strong co-agreements in North America and Europe, including rumors of a […]
Biotech Implosion: Favrille (FVRL)
Tuesday, May 27th, 2008Submitted by BioHealth Investor Blog
Favrille, Inc. (NASDAQ: FVRL) may have just joined the realm of biotech zombies this morning, or close to it. The company announced Phase III results which failed to show statistically significant improvement in its primary endpoint, and this was the registration trial of Specifid following Rituxan in patients with follicular B-cell […]
Viva Vivus (VVUS)
Tuesday, May 27th, 2008Submitted by BioHealth Investor Blog
Vivus (VVUS) took at 25% one-day jump recently after good
news about one of its treatments.
The interim results from the drug, Qnexa, were released in
an abstract to be presented at the American Diabetes Association
conference next month. Vivus is pursuing Qnexa in a lead indication
for obesity.
How good was the news? Rodman & Renshaw […]
The Road Gets Harder For Aastrom Biosciences (ASTM)
Tuesday, May 27th, 2008Submitted by BioHealth Investor Blog
Aastrom Biosciences (ASTM) is off almost 70% over the
last year. The company operates in the stem cell arena
of biotech and its future is based on its proprietary Tissue
Repair Cell (TRC) technology. The market clearly does
not think much of ASTM’s prospects as it sits at $.38,
near its 52-week low.
When the company released […]
Health Economists - science or economics degree?
Thursday, May 22nd, 2008Submitted by THE HEALTH ECONOMICS BLOG
Recently I had an interesting conversation with an analyst at a biotech company seeking my advice as to career changes towards the area of health economics. The basic question many students or young analysts have is wether to persue an additional degree, stay in science (pharmacy, biostatistics, medicine etc.) and […]
Future pharmaceutical R&D strategies
Tuesday, May 20th, 2008Submitted by THE HEALTH ECONOMICS BLOG
From seeking alpha
seekingalpha.com
May 13th
Big Pharma’s failure to develop enough new blockbuster drugs is combining with other forces to drive fundamental changes in pharmaceutical research and development, according to Deloitte. Chief among these will be the emergence of “NewPharmaCos” concentrating on genotyped market segments. The companies may be startups or spinoffs […]
Ex-Merck CEO blasts drug price
Friday, May 9th, 2008Submitted by THE HEALTH ECONOMICS BLOG
May 08, 2008
The Star-Ledger
BUSINESS
The voice of Roy Vagelos carries some weight in the pharmaceutical industry.
The former chief executive of Merck, who now serves as chairman of two biotechnology companies, had some choice words about drug pricing during an annual meeting of the International Society of Medical Publication Professionals in Philadelphia.
Not […]
Market Access consultancies bubble forming up?
Tuesday, May 6th, 2008Submitted by THE HEALTH ECONOMICS BLOG
Folks, the whole health economics consultancy industry is changing and growing and I thought I post some food for thought and discussions among the readers. Since about last year there is an unbroken trend in new health economics, pricing & reimbursement, market access, health economics communications etc. consulting companies popping […]
SMS makes its way into US health care
Thursday, May 1st, 2008Submitted by BioHealth Investor Blog
by David E. Williams
Health Business Blog
Text messaging isn’t exactly big news. Most people have heard about it, even if they associate it only with teens who’ve given up talking on the phone or even meeting in person in order to spend their time texting. But text messaging has actually been slower […]
NatusConsolidates Newborn Hearing Loss Screening with Acquisition
Thursday, May 1st, 2008Submitted by BioHealth Investor Blog
by Doug Cress
Med Tech Sentinel
Natus Medical (BABY) announced yesterday that it will acquire SonaMed, a privately held company based in Waltham, MA.
SonaMed manufactures and markets the Clarity Screener for the screening of hearing loss in newborns. The company reported revenues of $3.5 million in 2007.
According to Jim Hawkins, Natus’ President and […]
